These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial. Li G; Cappuccini F; Marchevsky NG; Aley PK; Aley R; Anslow R; Bibi S; Cathie K; Clutterbuck E; Faust SN; Feng S; Heath PT; Kerridge S; Lelliott A; Mujadidi Y; Ng KF; Rhead S; Roberts H; Robinson H; Roderick MR; Singh N; Smith D; Snape MD; Song R; Tang K; Yao A; Liu X; Lambe T; Pollard AJ; Lancet; 2022 Jun; 399(10342):2212-2225. PubMed ID: 35691324 [TBL] [Abstract][Full Text] [Related]
10. Quantitative Analysis of SARS-CoV-2 Antibody Levels in Cancer Patients Post Three Doses of Immunization and Prior to Breakthrough COVID-19 Infections. Macrae K; Martinez-Cajas J; Bessai K; Abdulhamed A; Gong Y Curr Oncol; 2022 Sep; 29(10):7059-7071. PubMed ID: 36290831 [TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial in Indonesia. Fadlyana E; Setiabudi D; Kartasasmita CB; Putri ND; Rezeki Hadinegoro S; Mulholland K; Lancet Infect Dis; 2023 May; 23(5):545-555. PubMed ID: 36640798 [TBL] [Abstract][Full Text] [Related]
12. Comparison of the immunogenicity of ChAdOx1 nCoV-19 vaccine against the wild-type and delta variants in kidney transplant recipients and healthy volunteers. Watcharananan SP; Jaru-Ampornpan P; Sahawongcharoen S; Naitook N; Himananto O; Jongkaewwattana A; Setthaudom C; Rattanasiri S; Phuphuakrat A; Thakkinstian A; Mavichak V; Am J Transplant; 2022 May; 22(5):1459-1466. PubMed ID: 35090091 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses. Thiruvengadam R; Awasthi A; Medigeshi G; Bhattacharya S; Mani S; Sivasubbu S; Shrivastava T; Samal S; Rathna Murugesan D; Koundinya Desiraju B; Kshetrapal P; Pandey R; Scaria V; Kumar Malik P; Taneja J; Binayke A; Vohra T; Zaheer A; Rathore D; Ahmad Khan N; Shaman H; Ahmed S; Kumar R; Deshpande S; Subramani C; Wadhwa N; Gupta N; Pandey AK; Bhattacharya J; Agrawal A; Vrati S; Bhatnagar S; Garg PK; Lancet Infect Dis; 2022 Apr; 22(4):473-482. PubMed ID: 34838183 [TBL] [Abstract][Full Text] [Related]
14. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Hillus D; Schwarz T; Tober-Lau P; Vanshylla K; Hastor H; Thibeault C; Jentzsch S; Helbig ET; Lippert LJ; Tscheak P; Schmidt ML; Riege J; Solarek A; von Kalle C; Dang-Heine C; Gruell H; Kopankiewicz P; Suttorp N; Drosten C; Bias H; Seybold J; ; Klein F; Kurth F; Corman VM; Sander LE Lancet Respir Med; 2021 Nov; 9(11):1255-1265. PubMed ID: 34391547 [TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults. Niyomnaitham S; Quan Toh Z; Wongprompitak P; Jansarikit L; Srisutthisamphan K; Sapsutthipas S; Jantraphakorn Y; Mingngamsup N; Licciardi PV; Chokephaibulkit K Hum Vaccin Immunother; 2022 Nov; 18(6):2091865. PubMed ID: 35816053 [TBL] [Abstract][Full Text] [Related]
16. Trajectory of Humoral Responses to Two Doses of ChAdOx1 nCoV-19 Vaccination in Patients Receiving Maintenance Hemodialysis. Ling TC; Chen PL; Li NY; Ko WC; Sun CY; Chao JY; Shieh CC; Shen CF; Wu JL; Huang TC; Chao CH; Wang JR; Chang YT Microbiol Spectr; 2023 Feb; 11(2):e0344522. PubMed ID: 36809164 [TBL] [Abstract][Full Text] [Related]
17. A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India. Kulkarni PS; Padmapriyadarsini C; Vekemans J; Bavdekar A; Gupta M; Kulkarni P; Garg BS; Gogtay NJ; Tambe M; Lalwani S; Singh K; Munshi R; Meshram S; Selvavinayagam TS; Pandey K; Bhimarasetty DM; Ramakrishnan SR; Bhamare C; Dharmadhikari A; Vadakkedath R; Bonhomme CJ; Thakar M; Kurle SN; Kelly EJ; Gautam M; Gupta N; Panda S; Bhargava B; Shaligram U; Kapse D; Gunale B; EClinicalMedicine; 2021 Dec; 42():101218. PubMed ID: 34870133 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness, safety, and immunogenicity of half dose ChAdOx1 nCoV-19 COVID-19 Vaccine: Viana project. Valim V; Martins-Filho OA; Gouvea MDPG; Camacho LAB; Villela DAM; de Lima SMB; Azevedo AS; Neto LFP; Domingues CMAS; de Medeiros Junior NF; Moulaz IR; Dias LH; Miyamoto ST; Teixeira-Carvalho A; Mill JG; Front Immunol; 2022; 13():966416. PubMed ID: 36105814 [TBL] [Abstract][Full Text] [Related]
19. Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine. Kang YM; Minn D; Lim J; Lee KD; Jo DH; Choe KW; Kim MJ; Kim JM; Kim KN J Korean Med Sci; 2021 Nov; 36(46):e311. PubMed ID: 34845875 [TBL] [Abstract][Full Text] [Related]
20. Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial. Shaw RH; Liu X; Stuart ASV; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Dejnirattisai W; Dinesh T; Faust SN; Ferreira DM; Finn A; Green CA; Hallis B; Heath PT; Hill H; Lambe T; Lazarus R; Libri V; Long F; Mujadidi YF; Plested EL; Morey ER; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Screaton GR; Singh N; Turner DPJ; Turner PJ; Vichos I; Walker LL; White R; Nguyen-Van-Tam JS; Snape MD; Lancet Respir Med; 2022 Nov; 10(11):1049-1060. PubMed ID: 35690076 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]